Does ORELABRUTINIB Cause Malignant neoplasm progression? 6 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 6 reports of Malignant neoplasm progression have been filed in association with ORELABRUTINIB. This represents 4.6% of all adverse event reports for ORELABRUTINIB.
6
Reports of Malignant neoplasm progression with ORELABRUTINIB
4.6%
of all ORELABRUTINIB reports
4
Deaths
0
Hospitalizations
How Dangerous Is Malignant neoplasm progression From ORELABRUTINIB?
Of the 6 reports, 4 (66.7%) resulted in death.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ORELABRUTINIB. However, 6 reports have been filed with the FAERS database.
What Other Side Effects Does ORELABRUTINIB Cause?
Anaemia (54)
Hypokalaemia (40)
Pneumonia (35)
Neutropenia (30)
Thrombocytopenia (26)
Disease progression (14)
Covid-19 (11)
Platelet count decreased (11)
Drug ineffective (10)
Myelosuppression (10)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which ORELABRUTINIB Alternatives Have Lower Malignant neoplasm progression Risk?
ORELABRUTINIB vs ORENCIA
ORELABRUTINIB vs ORITAVANCIN
ORELABRUTINIB vs ORITAVANCIN DIPHOSPHATE
ORELABRUTINIB vs ORLISTAT
ORELABRUTINIB vs ORNIDAZOLE